Lars Lannfelt

Research interests

Publications

• Lecanemab, Aducanumab, and Gantenerumab — Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease

  Neurotherapeutics · 2022 · 10.1007/s13311-022-01308-6

• A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer’s disease with lecanemab, an anti-Aβ protofibril antibody

  Alzheimer s Research & Therapy · 2021 · https://doi.org/10.1186/s13195-021-00813-8

• The Amyloid-β Pathway in Alzheimer’s Disease

  Molecular Psychiatry · 2021 · https://doi.org/10.1038/s41380-021-01249-0

• Alzheimer’s disease pathology propagation by exosomes containing toxic amyloid-beta oligomers

  Acta Neuropathologica · 2018 · 10.1007/s00401-018-1868-1

• Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

  Alzheimer s Research & Therapy · 2016 · 10.1186/s13195-016-0181-2

• Accumulation of amyloid-β by astrocytes result in enlarged endosomes and microvesicle-induced apoptosis of neurons

  Molecular Neurodegeneration · 2016 · 10.1186/s13024-016-0098-z

• η-Secretase processing of APP inhibits neuronal activity in the hippocampus

  Nature · 2015 · 10.1038/nature14864

• Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients

  Proceedings of the National Academy of Sciences · 2014 · 10.1073/pnas.1408900111

• Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease

  Alzheimer s & Dementia · 2014 · 10.1016/j.jalz.2014.10.009

• Extracellular Alpha-Synuclein Oligomers Modulate Synaptic Transmission and Impair LTP Via NMDA-Receptor Activation

  Journal of Neuroscience · 2012 · 10.1523/jneurosci.0234-12.2012

• PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses

  Journal of Alzheimer s Disease · 2010 · 10.3233/jad-2010-1390

• Stabilization of neurotoxic Alzheimer amyloid-β oligomers by protein engineering

  Proceedings of the National Academy of Sciences · 2010 · 10.1073/pnas.1001740107

• Safety, efficacy, and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial

  The Lancet Neurology · 2008 · https://doi.org/10.1016/s1474-4422(08)70167-4

• Sensitive ELISA detection of amyloid‐β protofibrils in biological samples

  Journal of Neurochemistry · 2007 · 10.1111/j.1471-4159.2007.04759.x

• The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Aβ protofibril formation

  Nature Neuroscience · 2001 · 10.1038/nn0901-887

• Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17

  Nature · 1998 · https://doi.org/10.1038/31508

• Human beta-2 adrenoceptor gene polymorphisms are highly frequent in obesity and associate with altered adipocyte beta-2 adrenoceptor function.

  Journal of Clinical Investigation · 1997 · 10.1172/jci119854

• Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

  Nature Medicine · 1996 · https://doi.org/10.1038/nm0896-864

• The structure of the presenilin 1 (S182) gene and identification of six novel mutations in early onset AD families

  Nature Genetics · 1995 · 10.1038/ng1095-219

• The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway

  Nature Medicine · 1995 · 10.1038/nm1295-1291

• Familial Alzheimer's disease in kindreds with missense mutations in a gene on chromosome 1 related to the Alzheimer's disease type 3 gene

  Nature · 1995 · https://doi.org/10.1038/376775a0

• Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging.

  Proceedings of the National Academy of Sciences · 1994 · 10.1073/pnas.91.18.8378

• Excessive production of amyloid beta-protein by peripheral cells of symptomatic and presymptomatic patients carrying the Swedish familial Alzheimer disease mutation.

  Proceedings of the National Academy of Sciences · 1994 · 10.1073/pnas.91.25.11993

• APOLIPOPROTEIN-E GENOTYPE AND ALZHEIMERS-DISEASE

  UCL Discovery (University College London) · 1993

• A pathogenic mutation for probable Alzheimer's disease in the APP gene at the N–terminus of β–amyloid

  Nature Genetics · 1992 · https://doi.org/10.1038/ng0892-345

Current projects

No projects listed.